Resources Archive - WuXi Biology

Simultaneous In Vitro Profiling of Anticancer Efficacy and Toxicity

Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...

EpCAM-CD3 BsAb-Encoding mRNA Suppresses Lung Tumors

Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...

Synthetic-Lethality Screening with PARP1 inhibition

PARP1 plays a central role in DNA repair and is a well-established target across multiple cancer types. Understanding the vulnerabilities...

In Vitro and In Vivo Efficacy of CAR-T Delivery

Targeted lipid nanoparticles (tLNPs) are advancing in vivo CAR-T therapies by facilitating the in situ generation of CAR-T effectors, offering...

In Vivo Evaluation of VEGF-Targeted Bispecific Antibodies

As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These...

Drug-Resistant KRAS G12D Lung Cancer Models

KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge. Understanding how that resistance develops is critical...

In Vivo CAR-T Preclinical Evaluation Platform

CAR-T therapies have transformed the treatment of hematologic malignancies, yet complex manufacturing, long production timelines, and high costs continue to...

A Novel Preclinical Mouse Model of Neutrophilic Asthma

Neutrophilic asthma remains one of the most challenging forms of asthma to study, with limited preclinical models available to support...

Advancing Conjugated Therapeutics: From ADC Innovation to Integrated Bioanalysis Strategies

Conjugated therapeutics, including antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs), are reshaping the future of targeted therapies and driving new...

Knowledge Library